Innovative Medicines Initiative
| Innovative Medicines Initiative | |
| Joint Technology Initiative on Innovative Medicines | |
| Keywords | Drug discovery, Drug development |
|---|---|
| Funding agency | European Commission European Federation of Pharmaceutical Industries and Associations (EFPIA) |
| Project type | Joint Technology Initiative (JTI) |
| Reference | |
| Objective | Re-invigorate the European bio-pharmaceutical sector and to make Europe more attractive for private research and development (R&D) investment in this sector |
| Participants | |
| Budget | Overall: 2 billion EUR Funding: 1 billion EUR |
| Duration | 2008 - 2017 |
| Web site | http://imi.europa.eu |
The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (Public-Private Partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme.
The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks.
The Sixth Framework Programme's research projects InnoMed AddNeuroMed and InnoMed PredTox act as pilot projects establishing the feasibility of this particular public-private partnership[1].
See also
References
- Hughes V., Europe pledges billions to solve its drug development woes, Nat Med. 2008 Feb;14(2):107
- Innovative Medicines Initiative
- Technology Platform for Innovative Medicines
- Fact sheet provided by the European Commission
External links
- [2] IMI website
- Innovative Medicines Initiative European Commission website
- Innovative Medicines Initiative EFPIA website